Influence of antiretroviral therapy and periodontal disease on human salivary beta-defensin 2 in patients infected with HIV.
Studies have addressed periodontal disease biomarkers in salivary proteins associated with innate immunity, mostly due to the alteration in the concentration of many of these proteins in the presence of inflammation. On the other hand, some systemic diseases can modify salivary protein concentrations, which may change their importance or role as specific biomarkers. To study the relationship between periodontal disease and concentrations of human beta-defensin 2 (HBD-2) in the saliva of patients infected and not infected with HIV. To evaluate the association between HBD-2 salivary concentration and viral load, the TCD4+ lymphocyte count (LTCD-4+) and the use of antiretroviral therapy (ART) was assessed in HIV infected patients. Concentrations of HBD-2 were measured in 48 patients not infected with HIV and 53 HIV-infected patients by ELISA, and these data were compared according to periodontal status. Within the group of HIV-infected patients, measures of HBD-2 were assessed according to viral load, LTCD-4+ count and the use of ART. Concentrations of salivary HBD-2 were associated with periodontal disease in non-HIV-infected patients. In HIV-infected patients, salivary HBD-2 was associated with serum status and the use of ART, but it was not related to the periodontal condition. The presence of HBD-2 in the saliva of HIV-infected patients showed no correlations with LTCD-4+ count or viral load. HBD-2 could be a periodontal biomarker in non-HIV-infected patients, but in HIV-infected patients, while salivary HBD- 2 was influenced by the serum status and ART use, it was not correlated with the periodontal condition.